Cardiovascular implications of hypoglycemia in diabetes mellitus

Circulation

Volumn 132, Issue 24, 2015, Pages 2345-2350

  Connelly, Kim A ^a   Yan, Andrew T ^a   Leiter, Lawrence A ^a   Bhatt, Deepak L ^b   Verma, Subodh ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADRENERGIC SYSTEM; AGE DISTRIBUTION; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COGNITION; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART RATE VARIABILITY; HEART WORK; HYPOGLYCEMIA; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PLATELET REACTIVITY; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; CARDIOVASCULAR DISEASES; CASE REPORT; COMPLICATION; HUMAN; MALE; RISK FACTOR; VERY ELDERLY;

AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; RISK FACTORS;

EID: 84952362321     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.015946     Document Type: Article

References (23)

1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137-149. doi: 10.1016/j. diabres.2013.11.002.
2. Emerging Risk Factors Collaboration, Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J. Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med. 2011;364:829-841. doi: 10.1056/NEJMoa1008862.
3. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384-1395. doi: 10.2337/dc12-2480.
4. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140-1147.
5. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139. doi: 10.1056/NEJMoa0808431.
6. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. Long-Term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818-828. doi: 10.1056/NEJMoa1006524.
7. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572. doi: 10.1056/NEJMoa0802987.
8. Chico A, Vidal-Ríos P, Subirà M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care. 2003;26:1153-1157.
9. Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middleaged patients with type 2 diabetes. Diabetes Care. 2009;32:1513-1517. doi: 10.2337/dc09-0114.
10. ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN Trial. Diabetes Care. 2015;38:22-28. doi: 10.2337/dc14-1329.
11. Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: The role of hypoglycemia. Circulation. 2011;123:342-348. doi: 10.1161/CIRCULATIONAHA.110.948489.
12. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371:1392-1406. doi: 10.1056/NEJMoa1407963.
13. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Macaya C. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430-2435.
14. Bedenis R, Price AH, Robertson CM, Morling JR, Frier BM, Strachan MW, Price JF. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2014;37:3301-3308. doi: 10.2337/dc14-0908.
15. Sommerfield AJ, Wilkinson IB, Webb DJ, Frier BM. Vessel wall stiffness in type 1 diabetes and the central hemodynamic effects of acute hypoglycemia. Am J Physiol Endocrinol Metab. 2007;293:E1274-E1279. doi: 10.1152/ajpendo.00114.2007.
16. Ziegler D, Zentai CP, Perz S, Rathmann W, Haastert B, Döring A, Meisinger C; KORA Study Group. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: The MONICA/KORA Augsburg Cohort Study. Diabetes Care. 2008;31:556-561. doi: 10.2337/dc07-1615.
17. Stahn A, Pistrosch F, Ganz X, Teige M, Koehler C, Bornstein S, Hanefeld M. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care. 2014;37:516-520. doi: 10.2337/dc13-0600.
18. Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: A network meta-Analysis. Diabetes Obes Metab. 2012;14:810-820. doi: 10.1111/j.1463-1326.2012.01606.x.
19. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326. doi: 10.1056/NEJMoa1307684.
20. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-1335. doi: 10.1056/NEJMoa1305889.
21. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373:232-242. doi: 10.1056/NEJMoa1501352.
22. Pfeffer MA, Diaz R, McMurray JJV, Lewis EF, Riddle MC, Gerstein HC. The Evaluation of Lixisenatide in Acute Coronary Syndrome-The Results of ELIXA. American Diabetes Association, 75th Scientific Sessions, June 5-9, 2015, Boston, MA.
23. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [published online ahead of print September 17, 2015]. N Engl J Med. doi: 10.1056/NEJMoa1504720. http://www.nejm.org/doi/full/10.1056/NEJMoa1504720. Accessed November 5, 2015.